Eli Lilly's baricitinib, which has been shown to cut recovery time from coronavirus when combined with remdesivir, has been approved as a once-a-day eczema treatment, as reported This is Money on Tuesday.
The drug, which will have the brand name Olumiant for treating eczema, is now available across Europe for adults with moderate to severe eczema.
Olumiant has yet to be approved for eczema use on the NHS by the National Institute for Health and Care Excellence, but people can obtain a private prescription.